Neuronetics (STIM) Competitors

MiMedx Group (NASDAQ:MDXG) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Do analysts prefer MDXG or STIM?

MiMedx Group presently has a consensus target price of $12.50, suggesting a potential upside of 81.53%. Neuronetics has a consensus target price of $5.50, suggesting a potential upside of 36.99%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe MiMedx Group is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Does the MarketBeat Community prefer MDXG or STIM?

Neuronetics received 78 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 83.61% of users gave MiMedx Group an outperform vote while only 68.62% of users gave Neuronetics an outperform vote.

Company	Underperform	Outperform
MiMedx Group	Outperform Votes 51 83.61%	Underperform Votes 10 16.39%
Neuronetics	Outperform Votes 129 68.62%	Underperform Votes 59 31.38%

Is MDXG or STIM more profitable?

MiMedx Group has a net margin of 23.86% compared to Neuronetics' net margin of -50.09%. MiMedx Group's return on equity of 26.21% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	23.86%	26.21%	18.15%
Neuronetics	-50.09%	-141.24%	-32.77%

Do institutionals and insiders believe in MDXG or STIM?

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by insiders. Comparatively, 8.7% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer MDXG or STIM?

In the previous week, MiMedx Group had 1 more articles in the media than Neuronetics. MarketBeat recorded 4 mentions for MiMedx Group and 3 mentions for Neuronetics. MiMedx Group's average media sentiment score of 1.69 beat Neuronetics' score of 0.39 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Neuronetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, MDXG or STIM?

MiMedx Group has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500.

Which has better valuation & earnings, MDXG or STIM?

MiMedx Group has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$352.38M	2.89	$58.23M	$0.27	25.50
Neuronetics	$89.45M	2.95	-$30.19M	-$1.31	-3.06

Summary

MiMedx Group beats Neuronetics on 13 of the 17 factors compared between the two stocks.